What do systematic reviews say?

Fluoxetine vs pramipexole

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with pramipexole (low certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.49 [0.05, 4.51]
  1 study · 105 participants
  Low

Fluoxetine vs reboxetine

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with reboxetine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.92 [0.47, 1.77]
  3 studies · 464 participants
  Moderate

Fluoxetine vs sertraline

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with sertraline (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.09 [0.68, 1.77]
  5 studies · 1056 participants
  Moderate

Fluoxetine vs tianeptine

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with tianeptine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.82 [0.27, 2.53]
  3 studies · 830 participants
  Moderate

Fluoxetine vs trazodone

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with trazodone (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.23 [0.04, 1.51]
  2 studies · 70 participants
  Moderate

Fluoxetine vs venlafaxine

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with venlafaxine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.31 [0.91, 1.89]
  13 studies · 2640 participants
  Moderate

Fluoxetine vs agomelatine

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with agomelatine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.08 [0.41, 2.88]
  2 studies · 785 participants
  Moderate

Fluoxetine vs amineptine

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with amineptine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.04 [0.19, 5.57]
  1 study · 63 participants
  Moderate

Fluoxetine vs AMISULPRIDE

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with amisulpride (low certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.16 [0.43, 3.1]
  1 study · 281 participants
  Low

Fluoxetine vs bupropion

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with bupropion (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.16 [0.33, 4.1]
  2 studies · 436 participants
  Moderate

Fluoxetine vs citalopram

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with citalopram (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.87 [0.48, 1.56]
  3 studies · 732 participants
  Moderate

Fluoxetine vs Crocus sativus

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Fluoxetine vs duloxetine

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with duloxetine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 3.33 [0.93, 12.11]
  2 studies · 432 participants
  Moderate

Fluoxetine vs escitalopram

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with escitalopram (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.74 [0.46, 6.53]
  2 studies · 578 participants
  Moderate

Fluoxetine vs tricyclic antidepressants (TCAs)

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with TCAs (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.29 [0.96, 1.72]
  33 studies · 2911 participants
  Moderate

Fluoxetine vs fluvoxamine

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Fluoxetine vs hypericum

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with hypericum (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 4.7 [0.22, 99.39]
  2 studies · 401 participants
  Moderate

Fluoxetine vs maprotiline

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with maprotiline (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 2.54 [0.33, 19.9]
  3 studies · 209 participants
  Moderate

Fluoxetine vs mianserin

It is very uncertain whether fluoxetine changes failure to complete ‐ inefficacy ‐ compared with mianserin (very low certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 2.27 [0.38, 13.63]
  1 study · 53 participants
  Very low

Fluoxetine vs milnacipran

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with milnacipran (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.25 [0.68, 2.3]
  3 studies · 560 participants
  Moderate